You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Intracellular Detection of Small Molecules in Live Cells

    SBC: AGAVE BIOSYSTEMS INC.            Topic: AF11BT09

    ABSTRACT: Protection of first responders who are exposed to hazards including chemical warfare agents (CWAs) is a very critical need. The need is derived from not only their welfare but their ability to respond, protect the community and provide logistical support to the response. A simple exposure monitor would provide critical information to the first responder and allow them to respond accor ...

    STTR Phase II 2014 Department of DefenseAir Force
  2. Pantograph: Secure, Cross-domain Object Models

    SBC: ATC-NY INC            Topic: AF13AT08

    ABSTRACT: Most cross-domain information flows require some human intervention to ensure that the requirements for releasability are met. Such intervention is expensive and slow, and can form a bottleneck in operations. Unfortunately, fully automated sharing of information across security domain boundaries is also fraught with difficulties due to problems with identifying releasable information, a ...

    STTR Phase I 2014 Department of DefenseAir Force
  3. Secure Efficient Cross-domain Protocols

    SBC: SONALYSTS INC            Topic: AF13AT08

    ABSTRACT: The Sonalysts team proposes to develop a solution that facilitates the flow of data between different levels of classification while improving and ensuring both security and data integrity. Our approach involves a set of protocols that provide a unique and disruptive combination of multichannel data dispersion and multi-classification data management techniques to meet our objectives. ...

    STTR Phase I 2014 Department of DefenseAir Force
  4. Broad-Spectrum PV Devices Based on Charged Quantum Dots

    SBC: Optoelectronic Nanodevices LLC            Topic: AF13AT13

    ABSTRACT: This project addresses the need for high-efficiency broad-spectrum PV cells. The proposed original PV design is based on quantum dots with built-in charge (Q-BIC), where the dot charging is realized by selective doping of dot medium. The preliminary data demonstrate that the charged dots placed in a single p-n-junction strongly enhance harvesting and conversion of sub-bandgap photons an ...

    STTR Phase I 2014 Department of DefenseAir Force
  5. High efficiency up- and down-converting infrared nanoparticles

    SBC: Nanoscience Solutions, LLC            Topic: AF11BT24

    ABSTRACT: This Phase II proposal will capitalize on the success of Phase I to further develop stable and optically efficient fluorescent particles that absorb and emit light in the infrared part of the spectrum and lack any visible light emissions. The specific goals of Phase II will be to further research infrared nanoparticles to increase their brightness with an emphasis on production scalabi ...

    STTR Phase II 2014 Department of DefenseAir Force
  6. Orally available transition state inhibitors for triple negative breast cancer

    SBC: NANOMETICS LLC            Topic: NCI

    Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Modified RNA tools and diagnostics for drug abuse

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government